ArticleClinical kidney journal2025
Regional citrate anticoagulation ensures safe and effective kidney replacement therapy in metformin-associated lactic acidosis.
Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metformin-associated lactic acidosis (MALA) is a rare but potentially life-threatening complication of metformin therapy, often associated with acute kidney injury (AKI). Sustained low-efficiency dialysis (SLED) offers both haemodynamic stability and effective metformin clearance. However, during regional citrate anticoagulation (RCA), concerns may arise regarding citrate accumulation due to metformin-induced impairment of cellular metabolism. This study assesses the efficacy and safety of SLED with RCA in the management of MALA, providing direct measurements of serum metformin and citrate levels to evaluate drug clearance and potential citrate accumulation. Methods: A prospective observational study was conducted on consecutive critically ill patients with severe AKI and suspected MALA undergoing a 16-h SLED session with RCA. Demographic, clinical and laboratory data were collected. Serum metformin and citrate levels were measured via high-performance liquid chromatography and enzymatic spectrophotometric analysis, respectively. Mixed effects linear models were used to analyse serum metformin, lactate, citrate, electrolytes and acid-base parameters over time. Results: Twenty-three patients (median age 79 years; APACHE II score 29) had metformin levels at intensive care unit (ICU) admission above the therapeutic range (median 29.1 mg/l; normal: 0.5-3). ICU mortality was 22% ( Conclusions: SLED with RCA is safe and effective in patients with MALA, ensuring adequate KRT duration, rapid metformin clearance and acid-base status restoration. Direct citrate measurements confirmed the absence of accumulation, reinforcing RCA as a viable anticoagulation strategy in this clinical setting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.